Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 24, 2007 Billy Fisher	A Fountain of Youth? A study sponsored by Sirtris Pharmaceutical shows potential for the fight against aging. Investors, take note.
The Motley Fool April 23, 2008 Brian Lawler	Glaxo's Three-Quarter-Billion-Dollar Gamble Glaxo adds another development stage drugmaker to its portfolio. Investors take note.
The Motley Fool November 10, 2004 Tom Taulli	Small-Cap IPOs Back in Action And they're just as volatile as ever.
The Motley Fool August 18, 2010 Travers & Jayson	Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool December 28, 2007 Brian Orelli	The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007.
The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
The Motley Fool April 5, 2011 Frank Vinluan	Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat.
The Motley Fool August 17, 2010 Travers & Jayson	How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
The Motley Fool August 27, 2010 Travers & Jayson	The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science.
The Motley Fool August 17, 2010 Travers & Jayson	Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy.
The Motley Fool August 26, 2010 Travers & Jayson	Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing?
The Motley Fool August 24, 2010 Travers & Jayson	Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool April 27, 2010 Brian Orelli	Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
Bio-IT World May 2006 G. Steven Burrill	Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies.
The Motley Fool June 7, 2007 Brian Lawler	Are You Ignoring the Most Exciting Stocks? Never considered drug stocks? You're missing some of the market's best investments.
The Motley Fool August 18, 2010 Travers & Jayson	Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
The Motley Fool August 17, 2010 Travers & Jayson	Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
The Motley Fool June 21, 2011 Alexander Crawford	Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list?
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
The Motley Fool January 9, 2008 Brian Orelli	Sirtris' Diabetes Drug: Safe, but Is It Effective? Sirtris has exciting drugs, but is still a pretty risky investment. Investors, this may be one to keep an eye on.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
The Motley Fool October 27, 2005 Nathan Slaughter	Halloween Trick: APEX Mid-Cap Growth Fund This fund will have shareholders running for their lives: Only five of the top 25 holdings have managed to avoid a loss, and the fund overall has plummeted 23% on the year.
Bio-IT World August 2005 G. Steven Burrill	Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool March 8, 2006 Tim Hanson	IPOs' Dirty Little Secret There's optimism around the market's newest offerings, but is it warranted? Many IPOs just flat out fail to perform over long periods of time. Investors -- never buy the hype and never overpay.
The Motley Fool May 5, 2004 Brian Gorman	Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas.
The Motley Fool May 30, 2008 Brian Orelli	WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Entrepreneur November 2006 Dian Vujovich	Track All-Star Highly ranked small cap shows steady growth.
BusinessWeek June 13, 2005 Arlene Weintraub	Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances.
The Motley Fool April 18, 2006 Tom Taulli	An ETF for New Stocks IPOs become the latest to join the ETF party. The IPOX-100 Index Fund is essentially a mid-cap index -- with a nice marketing angle.
BusinessWeek March 20, 2006	Biotech's Diet In A Bottle Could Extend Your Life A handful of biotech companies are developing drugs that produce the effects of caloric restriction in the body without depriving people of food.
The Motley Fool November 30, 2007 Brian Orelli	Increased Potency Increases Stock Price Sirtris Pharmaceuticals publishes an article this week in Nature that characterized its discovery of drugs that are 1000 times more potent than resveratrol, the compound found in red wine that makes mice live longer and lowers blood sugar levels in obese mice.
Managed Care August 2004	MCOs, Drug Manufacturers Have Lots of PR Work to Do Managed care companies, and pharmaceuticals especially, receive disheartening numbers in a consumer satisfaction poll.
The Motley Fool December 14, 2004 Charly Travers	Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool February 9, 2006 Brian Gorman	Charles River Bets on Preclinical The company is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly and Pfizer. But a large expansion in preclinical capacity warrants close watching. Investors, take note.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
The Motley Fool September 22, 2006	The IPO Lock-Up Period Before you get involved in an initial public offering, learn how IPOs work.
The Motley Fool June 25, 2008 Brian Orelli	WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play?
The Motley Fool March 14, 2008 Brian Orelli	No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company.